The numbers come first. Eight Sleep closed a $50 million round in March 2026 led by Tether, the company behind the world's largest stablecoin, pushing its valuation to $1.5 billion. The company has raised more than $310 million in total across a funding ladder that includes a $14 million Series B in 2018, an $86 million Series C in 2021 near a $500 million valuation, and a $100 million Series D in August 2025 near $1 billion.
The startup, founded in 2014 by Matteo Franceschetti, Massimo Andreasi Bassi, and Alexandra Zatarain, now sells in 35 countries — including a 2026 launch in China. Third-party estimates placed 2025 revenue at roughly $264 million, flat with 2024, according to Fortune. The company has never disclosed revenue officially, and Franceschetti declined to confirm specifics. Eight Sleep reported being profitable in 2025.
The strategic pivot is medical. Franceschetti told Fortune the company began pursuing FDA clearance for sleep apnea detection and mitigation technologies in 2025, and that the filing is progressing 'fairly smoothly.' The goal is not merely to flag apnea risk — as Apple Watch and Samsung's Galaxy Watch already do under FDA clearance granted since 2024 — but to quantify apnea events per hour, a more clinical, prescription-based diagnostic standard.
In August 2026, Eight Sleep launched a clinical trial with Abu Dhabi's Department of Health to test whether its Pod device can automatically reposition sleep apnea patients, potentially serving as an alternative to a CPAP machine. The move follows a pattern: Oura signed a joint research program with the same Abu Dhabi body on women's health, while Whoop secured a $75 million investment and research partnership with Mubadala. U.S. consumer health-tech firms are using the emirate as a credibility springboard.
The product itself sits atop a mattress and connects to a hub that circulates heated or cooled water through internal tubing, with each side of the bed running an independent heat zone. Built-in sensors track heart rate, breathing, and movement; an AI model adjusts temperature through the night and generates a sleep score. Full automatic control requires an annual subscription priced between $199 and $399. The Pod already qualifies for HSA and FSA reimbursement through fintech platform Truemed.
Formula 1 driver Charles Leclerc holds a position on the company's investor cap table. Aston Martin Aramco signed on as a team partner in February 2026 in a reportedly 'eight-figure' deal. Franceschetti's stated ambition, as told to Fortune, is to build 'the biggest health technology company in the world.'
Currently, Eight Sleep has published one independent study on the Pod's benefits alongside several directionally positive preprints not yet independently verified. Several company-funded studies on sleep apnea have appeared in scientific journals.
CEO Times reads this as a clean free-market play. A hardware startup that bootstrapped credibility through an Indiegogo campaign, survived two Y Combinator rejections, and reached profitability without government subsidy is now attempting to disrupt a healthcare reimbursement system that has long rewarded incumbents over innovators. If FDA clearance follows, insurers — not just billionaires — become the customer, and the addressable market expands by an order of magnitude. Capital rewards clear rules, and Eight Sleep is betting the regulatory lane, however narrow, is worth the climb.
